论文部分内容阅读
Objective:The aim of this study was to investigate the clinicopathologic and prognostic factors of the partial subtypes of lung adenocarcinoma,including pure brenchioloalveolar carcinoma (BAC),adenocarcinoma (AC) with BAC component and AC without BAC component.Methods:One hundred and six adenocarcinoma specimens which were followed up completely for 3 years,were obtained from 106 patients (45 men and 61 women) who underwent surgical resection for pathologically confirmed pulmonary adenocarcinoma in the Cancer Hospital of Tianjin Medical University,from June 2004 to December 2005.According to the recent 2004 World Health Organization (WHO) pathological classification criteria of lung cancer,lung adenocarcinomas were divided into three subgroups:pure BAC,AC with BAC component and AC without BAC component.The clinical data were retrospectively analyzed based on statistical methods.All data were analyzed using SPSS statistics software and Kaplan-Meier survival curves were constructed,meanwhile,we conducted a Log-rank test.Results:The statistical analysis showed that no significant association was found among the three groups in gender and age; however,smoke index,tumor size,N stage,TNM stage,postoperative recurrence and metastasis had a statistically significant correlation among three groups (P＜0.01).The 3-year survival rates of the three groups were 96.4%,61.0% and 40.5% respectively,which had a statistically significant difference.And the 3-year survival rate was significantly higher in the patients with pure BAC than in the patients with other types of lung adenocarcinomas (P＜0.01).In contrast to the other two groups (pure BAC and AC with BAC component),we found the evidence that the 3-year prognosis of lung adenocarcinoma without BAC component was worse than the two formers.Conclusion:The three groups (pure BAC,AC with BAC component and AC without BAC component) have their own distinct clinicopathologic features respectively and completely different clinical prognosis.The strict distinction of the subtypes of lung adenocarcinoma can provide more reliable basis for scientific and comprehensive clinical treatment and contribute to assess the clinical prognosis effectively.